# Training Session on enhancement of Dyslipidaemia

Family Doctor, DHC Nurse for CDCC

**Date: 24 March 2025** 




# Training Session on Enhancement of CDCC IT Systems

(for Nurse Clinic and Allied Health services)




Time	Duration	Topics	Speakers
13:30-13:45	15 mins	1. Introduction of Dyclinidaemia	HA ST
13.30-13.43	13 1111113	1. Introduction of Dyslipidaemia	Elgar
13:45-14:00	15 mins	2. Enhanced features of IT Contains	HA HI
13.45-14.00	15 1111115	2. Enhanced features of IT System	Olivia
			HA HI
14:00-14:10	10 mins	3. Live Demonstration – New Participant Screening	Olivia
			<b>3.1.1.0</b>
			HA HI
14:10-14:15	5 mins	4. Enhanced administrative features	Olivia

## **Existing CDCC Participant**



## **New enrolled CDCC Participant**



# **Enhancements for Dyslipidaemia**


- New lab test "Full Lipid Profile, Fasting" added to 4 packages in both Screening and Treatment phases
- New data field of JBS2 risk % for Screening Completion
- Rename "Hyperlipidaemia" to "Dyslipidaemia Screening", with condition added in Screening Phase
- Rename "Hyperlipidaemia" to "Dyslipidaemia" in Treatment Phase
- New Management plan for "Dyslipidaemia Screening"
- Modify management plan options for screening result

- New matrix of diagnosis and Management plan
- New criteria of screening completion
- Update Management Plan description in related system
- Quota management of new Mx plan
- Add new management plan option to PPM
- 12 Update Rescreening criteria
- 13 Historical data handling



# Use of IT Systems for CDCC - Diagnosis

# **Workflow of Consultation**



23-Nov-2023


Consultation







# **CDCC Screening Phase**






# CDCC uploaded investigation result with high-low flag, reference range and comment

*Consultation Date	25-Nov-2024		Curr	ent	
*Consultation Type	Face-to-Face (	Consultation OPh	one Consultation (Non-	subsidised)	
Assessment Invest	igation Result	Management	Preventive Care	Medication	
_atest Investigation Result U	ploaded From Lal	boratory Service Prov	rider		
Specimen collection date: Sodium (SI unit): Potassium (SI unit): Urea (SI unit): Creatinine (SI unit): Glucose, Fasting plasma (S Triglycerides (SI unit): Cholesterol, Total (SI unit): HDL Cholesterol (SI unit): LDL Cholesterol, Direct (SI u		10-Jul-2( 142 mm 3.9 mm 9.0 mm 158 um 4.7 mm 2.38 mm 7.23 mm 1.99 mm	5)/L  /L  /L  /L  /L  /L  0 /L		<b>≅</b> Remove
Supplementary Invest  + Manual Input	igation Result				
					Edit Cancel

New display: Latest uploaded structured lab result is auto-filled and displayed with high-low flag indicator in red color, tooltips (by mouse-over) with reference range & comment, when applicable.

Remark: Also enhanced with table format UI, and easier to differentiate from auto-filled result from "Supplementary Investigation Result (Manual Input)" when input if necessary.





# **Enhanced Diagnosis for Dyslipidaemia Screening**



*Consultation Date	04-Mar-2025				
*Consultation Type	● Face-to-Fac	e Consultation O Phon	e Consultation (Non-sul	bsidised)	
Assessment	Preventive Care	Investigation Result	Screening Result		
Diagnosis	HT Screening	<ul><li>Normal BP</li></ul>	O High Normal BP	Онт	
	DM Screening	<ul><li>Normal</li></ul>	O Prediabetes	O DM	_
	Dyslipidaemia S	Screening O Normal	*Dyslipidaemia	O N/A	
			O Specified Con-	dition of Dyslipidaemia [¹]	
			O Non Specified	Condition of Dyslipidaemia [1]	
	Estimated card	iovascular disease risk ba	ased on JBS 2 guideline	s [²]:	ars 🖶
	[1] Specified Cor 20%	ndition of Dyslipidaemia: Pa	rticipants with (1) LDL ≥	5.0 mmol/L; or (2) LDL 2.6 - < 5.0 mr	nol/L and CVD risk ≥
	Association. JB		guidelines on prevention	; HEART UK; Primary Care Cardiovas of cardiovascular disease in clinical	-
Note					•
Delete				Save	Cancel



# **Enhanced Diagnosis for Dyslipidaemia Screening**



*Consultation Date	04-Mar-2025			
*Consultation Type	● Face-to-Fac	e Consultation O Phon	e Consultation (Non-sul	bsidised)
Assessment	Preventive Care	Investigation Result	Screening Result	
Diagnosis	HT Screening	<ul><li>Normal BP</li></ul>	O High Normal BP	Онт
	DM Screening	<ul><li>Normal</li></ul>	O Prediabetes	O DM
	Dyslipidaemia S	Screening O Normal	Dyslipidaemia	O N/A
			O Specified Con-	dition of Dyslipidaemia [1]
			O Non Specified	Condition of Dyslipidaemia [1]
	Estimated card	liovascular disease risk ba	ased on JBS 2 guideline	s [²]: 🔻 🗸 % over 10 years 🗟
	[1] Specified Cor	ndition of Dyslipidaemia: Pa	rticipants with (1) LDL ≥	5.0 mmol/L; or (2) LDL 2.6 - < 5.0 mmol/L and CVD risk ≥
	20%			
	[²] British Cardia	c Society; British Hypertens	sion Society; Diabetes UK	; HEART UK; Primary Care Cardiovascular Society; Stroke
				of cardiovascular disease in clinical practice. Heart.
	2005 Dec;91 Su	ppl 5(Suppl 5):v1-52. doi: 10	J.1136/hrt.2005.079988.	
Note				•
Delete				Save Cancel



# **Enhanced Diagnosis for Dyslipidaemia Screening**



Estimated cardiovascular disease risk based on JBS 2 guidelines [2]:


√ % ov

🗸 % over 10 years 🖶

s Division of the second of th

[¹] Specified Condition of Dyslipidaemia: Participants with (1) LDL ≥ 5.0 mmol/L; or (2) LDL 2.6 - < 5.0 mmol/L and 71.20%

[2] British Cardiac Society; British Hypertension Society; Disconstruction. JBS 2: Joint British Societies' guidelines on per 2005 Dec;91 Suppl 5(Suppl 5):v1-52. doi: 10.1136/hrt.200:








# **Enhanced Management Plans in clinical note**





### **Management Plan**

### **Admit to Treatment Phase**

FU by family doctor for pre-DM (HbA1c 6.0-6.4%/ FPG 6.1-6.9 mmol/L) management without HT under the CDCC Pilot Scheme

FU by family doctor for DM and/or HT management under the CDCC Pilot Scheme (with dropdown options)

FU by family doctor for Specified Condition of Dyslipidaemia [1] management under the CDCC Pilot Scheme without pre-DM (HbA1c 6.0-6.4%/ FPG 6.1-6.9 mmol/L) / DM / HT

### **Not Admit to Treatment Phase**

Normal DM screening (without HT / Specified Condition of Dyslipidaemia [1])

Pre-DM management (HbA1c 5.7-5.9%/FPG 5.6-6 mmol/L) (without HT / Specified Condition of Dyslipidaemia [1])

Scheme Participant has pre-DM (HbA1c 6.0 -6.4%/FPG 6.1-6.9 mmol/L) / DM / HT / Specified Condition of Dyslipidaemia [1], but he/she does not opt for entering Treatment Phase



# Management Plan – Specified Condition of Dyslipidaemia management (without reason required)



Assessment	Preventive Care	Investigation Result	Screening Result	
Diagnosis	HT Screening	<ul><li>Normal BP</li></ul>	O High Normal BP	Онт
	DM Screening	<ul><li>Normal</li></ul>	O Prediabetes	O DM
	Dyslipidaemia S	Screening O Normal	<b>⊙</b> *Dyslipidaemia	O N/A
			<ul><li>Specified Cond</li></ul>	lition of Dyslipidaemia [¹]
			O Non Specified	Condition of Dyslipidaemia [¹]

Management Plan	Admit to Treatment Phase						
•	O FU by family doctor for Pre-DM management (HbA1c 6.0-6.4% / FPG 6.1-6.9 mmol/L) without HT under the CDCC Pilot Scheme						
	Reason for choosing pre-DM management plan that does not align with lab results						
	O FU by family doctor for DM and / or HT management under the CDCC Pilot Scheme						
	FU by family doctor for Specified Condition of Dyslipidaemia [1] management under the CDCC Pilot Scheme without Pre-DM (HbA1c 6.0-6.4% / FPG 6.1-6.9 mmol/L) / DM / HT  Reason for entering treatment phase under Non Specified Condition  Slipidaemia						



# Management Plan – Specified Condition of Dyslipidaemia management (with reason required)



Assessment	Preventive Care	Investigation Result	Screening Result	
Diagnosis	HT Screening	<ul><li>Normal BP</li></ul>	O High Normal BP	Онт
	DM Screening	<ul><li>Normal</li></ul>	O Prediabetes	O DM
	Dyslipidaemia S	Screening O Normal	<b>⊙</b> *Dyslipidaemia	O N/A
			O Specified Cond	ition of Dyslipidaemia [¹]
			Non Specified (	Condition of Dyslipidaemia [¹]

Management Plan	Admit to Treatment Phase					
•	O FU by family doctor for Pre-DM management (HbA1c 6.0-6.4% / FPG 6.1-6.9 mmol/L) without HT under the CDCC Pilot Scheme					
	Reason for choosing pre-DM management plan that does not align with lab results					
	O FU by family doctor for DM and / or HT management under the CDCC Pilot Scheme					
	<ul> <li>FU by family doctor for Specified Condition of Dyslipidaemia [¹] management under the CDCC Pilot Scheme without Pre-DM (HbA1c 6.0-6.4% / FPG 6.1-6.9 mmol/L) / DM / HT</li> <li>*Reason for entering treatment phase under Non Specified Condition of Dyslipidaemia</li> </ul>					



# Management Plan – Specified Condition of Dyslipidaemia management (with reason required)



Assessment	Preventive Care	Investigation Result	Screening Result		
Diagnosis	*HT Screening	O Normal BP	O High Normal BP	• HT	
	*DM Screening	O Normal	O Prediabetes		
	*Dyslipidaemia \$	Screening O Normal		O N/A  ndition of Dyslipidaemia [¹]  d Condition of Dyslipidaemia [¹]	<ul> <li>Dyslipidaemia</li> <li>N/A</li> <li>Specified Condition of Dyslipidaemia [¹]</li> <li>Non Specified Condition of Dyslipidaemia [¹]</li> </ul>

DCC Pilot Scheme		
Reason for choosing pre-DM mar	nagement plan that does not align with lal	b results
	r HT management under the CDCC Pilot	HT + DM management
cheme U by family doctor for Specified C	condition of Dyslipidaemia [1] managemer	nt under the CDCC Pilot Scheme
ithout Pre-DM (HhA1c 6.0-6.4% /	FPG 6.1-6.9 mmol/L) / DM / HT	




# **Enhanced Screening Summary**

Normal BP

Dyslipidaemia

Specified Condition of Dyslipidaemia [1]

Normal



- If "normal" or "N/A" is selected in [Dyslipidaemia Screening], footnote [1] will not be displayed
- If [Estimated cardiovascular disease risk based on JBS 2 guidelines [2] is not entered, footnote [2] will not be displayed






# Subsidised consultation quota for Specified Condition of Dyslipidaemia management

		Medical	Nurse	Allied Health session			
	Consultation		Clinic	Dietitian Physiotherapy		Podiatrist	Optometry
Pre-DM Management (HbA1c 6.0-6.4% / FPG 6.1-6.9 mmol/L)	Every year	4	2		3		
DM Management	Every year	6	2	4			
HT + DM Management	Every year	6	2	4			
	1 <sup>st</sup> year	C	2	4			
HT Management	2 <sup>nd</sup> year & onward	6	2	3			
LIT + Due DA4 Management	1 <sup>st</sup> year	6	2	4			
HT + Pre-DM Management	2 <sup>nd</sup> year & onward	6	2	3			
FU by family doctor for Specified Condition of Dyslipidaemia [1]	1 <sup>st</sup> year	4					
management under the CDCC Pilot Scheme without Pre-DM (HbA1c 6.0- 6.4% / FPG 6.1-6.9 mmol/L)/DM/HT	2 <sup>nd</sup> year & onward	2	2		3		



# **Quota for Specified Condition of Dyslipidaemia management**








# **Enhanced laboratory test packages for Dyslipidaemia Screening**



### **CDCC Treatment Phase**





# **Enhanced clinical note in Treatment Phase**



*Consultation Date	05-Mar-2025			
*Consultation Type	O Face-to-Face Consultatio	on    Phone Consultation	(Non-subsidised)	
Assessment	Investigation Result Manage	ement Preventive Ca	re Medication	
Problem	DM Dyslipidaemia Others, please specify	□ НТ	Prediat	petes
Management	<ul> <li>Disease Education         please specify</li> <li>Life Style Modification Ad         please specify</li> <li>Arrange Investigation</li> </ul>	lvice		
	Refer to allied health servi	ice		

# Live-demo on New Participant Screening







# **Historical Data handling**



Effective Date: 28 March 2025

Current and enhanced version are both available in CDCC IT System

Investigation Form

Clinical Note for Screening

Screening Summary Management Plan Display name of Management plan

Clinical Note for Treatment

Current version	Enhanced version
Investigation request created before effective date	Investigation request created after effective date
Clinical note for Screening created before effective date	Clinical note for Screening created after effective date
Screening completion on notes created before effective date	Screening completion on notes created after effective date
Clinical note for Treatment created before effective date	Clinical note for Treatment created after effective date



# **Enhancement on Participant Management**


















# **Enhancement on integration with other systems**





Management Plan	Display Name in other systems
Admit to Treatment Phase	
FU by family doctor for Pre-DM management (HbA1c 6.0-6.4% / FPG 6.1-6.9 mmol/L) without HT under the CDCC Pilot Scheme	FU by family doctor for Pre-DM management (HbA1c 6.0-6.4% / FPG 6.1-6.9 mmol/L) without HT under the CDCC Pilot Scheme
FU by family doctor for DM and/or HT management under the CDCC Pilot Scheme: [Display option of HT management]	HT management
FU by family doctor for DM and/or HT management under the CDCC Pilot Scheme: [Display option of HT+Pre-DM management]	HT + Pre-DM management
FU by family doctor for DM and/or HT management under the CDCC Pilot Scheme: [Display option of HT+DM management]	HT + DM management
FU by family doctor for DM and/or HT management under the CDCC Pilot Scheme: [Display option of DM management]	DM management
FU by family doctor for Specified Condition of Dyslipidaemia [¹] management under the CDCC Pilot Scheme without Pre-DM (HbA1c 6.0-6.4% / FPG 6.1-6.9 mmol/L) / DM / HT	Specified Condition of Dyslipidaemia management
Not Admit to Treatment Phase	
Normal DM screening (without HT / Specified Condition of Dyslipidaemia [1])	Normal DM screening (without HT / Specified Condition of Dyslipidaemia)
Pre-DM management (HbA1c 5.7-5.9% / FPG 5.6-6 mmol/L) (without HT / Specified Condition of Dyslipidaemia $[^1]$ )	Pre-DM management (HbA1c 5.7-5.9% / FPG 5.6-6 mmol/L) (without HT / Specified Condition of Dyslipidaemia)
Scheme Participant has pre-DM (HbA1c 6.0-6.4% / FPG 6.1-6.9 mmol/L) / DM / HT / Specified Condition of Dyslipidaemia [¹] , but he/she does not opt for entering Treatment Phase	N/A



# **Enhancement on integration with CMS On-ramp**












# **Enhancement on integration with eHealth App**











# **Enhancement on integration with eHealth App**












# **Training Kit of CDCC IT Modules**



Functions of CDCC IT Module [G139] (Revised in Jan 2025)











Q & A